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Objective: The management of infected aortic endografts is a challenging endeavor. Treatment of this problem has not
been well deﬁned as it is fairly uncommon. However, the incidence is increasing. This study examines the results of
treatment at a single center for this morbid process.
Methods: A retrospective review was performed of patients treated for infected abdominal or thoracic endograft infection
following previous abdominal or thoracic endovascular aneurysm repair. Data was reviewed for patient demographics,
details of initial endograft implantation, presentation and timeline of subsequent infection, management of infected
grafts, and outcomes during follow-up.
Results: Overall, 18 patients were treated for infected endografts (thoracic: six, abdominal:12). Three patients were
treated between 2000 and 2006, corresponding to a 0.6% institutional incidence of endograft infection (3/473). There
were no transfers for infected endografts from outside institutions. From 2006 to 2011, 15 patients underwent treat-
ment. Six were institutional cases of infections (6/945, 0.6% infection rate), however, there was an increase in transfers
(n [ 9). Median time to presentation with infection from endograft implant was 90 days, with over one-half (61%)
presenting within the ﬁrst 3 months. Tissue and/or blood cultures were positive in 12/16 growing Escherichia coli
(n [ 1), group A streptococcus (n [ 3), methicillin-resistant Staphylococcus aureus (n [ 3), or polymicrobial infections
(n [ 7). The other four patients were culture negative with computed tomography evidence of gas surrounding the
endograft and clinical sepsis. Ten patients (abdominal: eight, thoracic: two) were treated with endograft explantation.
The remaining eight patients were considered too high-risk for explant or refused open surgery and were therefore
managed conservatively without explant (abdominal: four, thoracic: four). At a mean follow-up of 24.7 months,
aneurysm-related mortality was 38.9% (n[ 7) and was higher for patients presenting with aortoenteric or aortobronchial
ﬁstulas (n [ 6/10, 60%) (P [ .04) and for thoracic stent infections (n [ 5/6; 83%) (P [ .03). The only survivor of
a thoracic infection was managed surgically. Overall survival for patients with abdominal endografts (n[ 12) was similar
between the eight patients managed surgically (n[ 6/8; 75%) and the four selected for medical management (n[ 4/4;
100%) (P [ .39). All survivors remain on long-term suppressive antibiotics. Two additional patients died of unrelated
causes during follow-up.
Conclusions: Endograft infection is a rare but increasing complication after abdominal or thoracic endovascular aneurysm
repair, which carries signiﬁcant associated morbidity and mortality. Most endograft infections occurred in proximity to
other types of infection, suggesting that bacterial seeding of the endograft was the source. Aortoenteric and aorto-
bronchial ﬁstulas are common presentations, which portend a signiﬁcantly worse prognosis. Thoracic endograft infec-
tions, which have the highest rate of ﬁstulization, have the worst outcomes. Surgical excision continues to be standard of
care but conservative management with intravenous antibiotics may be of beneﬁt in certain patients with abdominal
endograft infections. (J Vasc Surg 2013;58:1179-85.)Endograft infection, a rare and challenging delayed
complication of endovascular aortic surgery, has a reportedthe Division of Vascular Surgery, Department of Surgery, Hospital of
e University of Pennsylvania.
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://dx.doi.org/10.1016/j.jvs.2013.04.040incidence of 0.05% to 4.0%.1,2 Because of the rarity of this
condition, only scattered reports and a few series are avail-
able to provide insight into this serious problem.1-4
Concrete management strategies are, therefore, not well
deﬁned. Our purpose was to further deﬁne the presenta-
tion, management, and outcomes of treatment for these
patients at our institution.
METHODS
A retrospective review was performed of all patients
treated at the Hospital of the University of Pennsylvania
(HUP) for abdominal or thoracic endograft infections
following previous endovascular abdominal aortic aneu-
rysm repair (EVAR) or thoracic endovascular aneurysm
repair (TEVAR). Patients were identiﬁed from1179
Table I. Incidence of endograft infection before and
after 2006
2000-2006 2006-2011
Total endograft infection, No. 3 13
Referrals, No. 0 9
Institutional, No. 3 6
EVAR/TEVAR (Institutional), No. 473 945
Incidence of graft infection
(Institutional), %
0.6% 0.6%
EVAR, Endovascular abdominal aortic aneurysm repair; TEVAR, thoracic
endovascular aneurysm repair.
Table II. Demographics and presentation
No. (n ¼ 16) % or range
Sex, male 15 83
Mean age, years 69 51-81
Past medical history
Cardiac disease 11 69
Pulmonary disease 4 25
Diabetes 3 19
Renal insufﬁciency 0 0
Hepatic disease 3 19
Immunosuppression 2 13
Coincident malignancy 1 6
Anatomy
Abdominal graft 12 67
Thoracic graft 6 33
Mean time to presentation, days
after EVAR
182 0-730
<3 months 11 61
Presentation
Sepsis 13 72
Aortic ﬁstula 10 56
Rupture 2 11
Potential infectious source 12 67
Infected ﬁeld 3 17
Interval procedures 4 22
Interval infections 6 33
Mean time to infectious source, days
after EVAR
EVAR, Endovascular abdominal aortic aneurysm repair.
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went endovascular abdominal or thoracic aneurysm repair
at HUP. Follow-up records were then studied to locate
patients that developed graft infection. A similar review
of records was performed for patients undergoing explant
of thoracic or abdominal endografts at HUP to identify
patients who were referred to our institution for further
management of infected grafts initially placed at an outside
hospital. Finally, an evaluation of transfer records was used
to identify patients initially treated with endografts at an
outside hospital and managed at HUP nonoperatively for
endograft infection.
For each patient, history, presentation, details of infec-
tion, management, and eventual outcomes were examined.
Speciﬁcally, history was reviewed for demographics, details
of initial EVAR/TEVAR (institution, duration of implan-
tation, graft type), and intervening medical/surgical
history between time of initial endovascular repair and
subsequent presentation with infection.
Clinical indicators of infection and culture results were
analyzed. Indicators of endograft infection included serial
positive blood/graft cultures, esophagogastroduodeno-
scopy, or bronchoscopy ﬁndings of an aortoenteric or
-respiratory ﬁstula, radiological ﬁndings of gas collections
surrounding the endograft on computed tomography or
a white blood cell scan localizing to the endograft, and
intraoperative ﬁndings of ﬁstula involving the graft or puru-
lence surrounding the graft.
Management strategies were closely reviewed for type
and duration of antibiotic use and details of operative
interventions. Operative details included strategy of inter-
vention and reconstruction. Postoperative outcomes exam-
ined included length of intensive care unit and hospital
stay, morbidity, and mortality. Patient follow-up was eval-
uated by review of the electronic medical record.
Descriptive data was expressed as a mean 6 the stan-
dard deviation. The unpaired Student t-test was used to
examine statistical differences between two groups.
RESULTS
Between January 2000 and July 2011, 18 patients were
treated for endograft infection at HUP. Three patients
were treated before 2006, and 15 were treated between
2006 and 2011. After excluding the nine patients who
were transferred from an outside institution for manage-
ment of infections, the actual incidence of graft infection
in patients initially treated with EVAR/TEVAR at HUP
remained unchanged pre- and post-2006 at 0.6%
(Table I). However, there was a signiﬁcant increase in
transfers to our institution for management of infected
endografts.
Demographics are presented in Table II. The mean age
at presentation was 69.1 years of age with a male predom-
inance of patients (83%). Most were treated for infections
involving abdominal endografts (n ¼ 12; 67%), although
thoracic endograft infections were also encountered.
Endograft infections were observed with a variety of stent
grafts, including those with and without active ﬁxation.Speciﬁcally, abdominal infections were seen with Cook
Zenith (n ¼ 5) (Cook Inc, Bloomington, Ind), Gore
Excluder (n ¼ 3) (W. L. Gore, Flagstaff, Ariz), Medtronic
AneuRx (n ¼ 2) (Medtronic, Minneapolis, Minn), and
Talent (n ¼ 2) (Medtronic) grafts (P ¼ NS). Thoracic
infections were seen with both the Gore Tag (n ¼ 3)
(W. L. Gore) and Medtronic thoracic (n ¼ 1) (Medtronic)
endografts (P ¼ NS).
Over one-half of the patients (61%) presented with
infection within the ﬁrst 3 months after endograft place-
ment with a median time to presentation of 90 days
(mean, 182 days; range, 0-730 days). In the majority of
patients (n ¼ 12; 67%), a potential source of infection
was identiﬁed in proximity to the timing of endograft
infection (Table II). Speciﬁcally, three were implanted
in an infected ﬁeld. These included one aortoenteric
Fig 1. Aortoenteric and aortobronchial ﬁstulas were a common presentation of endograft infection in this series. The
patient above had an aortodoudenal ﬁstula seen on endoscopy prior to surgery (a). At time of operation, when the
aortic sac was entered, the stent graft was easily identiﬁed (b and c, blue arrows), as was a large defect in the duodenum
communicating with the graft (b and c, yellow arrows).
Table III. Diagnostic evaluation
Study performed
(n ¼18), No. (%)
Infection or
ﬁstula identiﬁed, No. (%)
Imaging
CTA 16 (89) 14 (78)
Invasive imaginga
Endoscopy 5 (28) 3 (60)
Bronchoscopy 3 (17) 3 (100)
Cultures
Blood cultures 12 (67) 10 (83)
Graft cultureb 10 (100) 7 (70)
CTA, Computed tomographic angiogram.
aInvasive imaging only done in selected patients with suspected aortoenteric
or aortobronchial ﬁstulas.
bGraft cultures were only obtainable in patients undergoing explant.
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acoabdominal aortic aneurysm, and one mycotic thoracic
pseudoaneurysm. The latter two aneurysms were only
noted to be infected in retrospect. The mycotic thora-
coabdominal aortic aneurysm was thought to be inﬂam-
matory preoperatively. The patient with the mycotic
pseudoaneurysm had recently undergone an esophageal
botox injection for achalasia that had likely caused the
mycotic aneurysm to develop. Four patients had interval
procedures within 4 months of presentation of the graft
infection (cholecystectomy, coronary artery bypass graft-
ing in an immunosuppressed liver transplant patient,
a brachial pseudoaneurysm excision with arteriovenous
graft placement, and a g-tube in an immunosuppressed
patient on chemotherapy). Lastly, another six had interval
infections leading to potential bacteremiadnamely groin
infection (n ¼ 2), pneumonia (n ¼ 1), pneumonia with
diverticulitis (n ¼ 1), urosepsis and cholangitis (n ¼ 1),
and neutropenic fevers with esophagitis (n ¼ 1).
Most commonly, patients presented with either
evidence of sepsis or aortic ﬁstula although aortic rupture
was also seen (Table II). Fig 1 demonstrates an aortoduo-
denal ﬁstula in a patient with an abdominal endograft
infection.
Details of diagnostic work-up at presentation are
demonstrated in Table III. A computed tomographic
angiogram (CTA) was obtained in the vast majority of
patients and demonstrated evidence of surrounding strand-
ing, air in the sac, or erosion into adjacent structures
(Fig 2). Endoscopy or bronchoscopy was often performed
in patients with concern for aortoenteric or aortobronchial
ﬁstulas. Laboratory evaluation was performed in all subjects
and the mean white blood cell count of patients at time of
presentation was 12.7 6 6.2 (range, 5.9-30.2). Blood and
graft cultures were obtained when possible and were posi-
tive in 83% and 70%, respectively. The most common blood
isolate was group A strep, however, most graft cultures
were polymicrobial. Methicillin-resistant Staphylococcus
aureus and E coli were also cultured in isolation (Fig 3).
Total endograft explantation was performed in 10
patients. Reconstruction was performed with ax-bifemoralbypass (n ¼ 5) or the use of in situ homograft (n ¼ 4)
or rifampin grafts (n ¼ 1) in the remaining patients. Alter-
natively, medical management was used without endograft
explantation in the remaining eight patients who were
either too high risk for endograft excision (n ¼ 3), refused
open operation (n ¼ 1), or had minimal evidence of graft
contamination (n ¼ 4). Four of these patients underwent
less invasive surgical procedures including three who
underwent groin debridements for source control and
one who underwent duodenal repair and reinforcing stent
graft placement. The latter patient additionally had
omentum placed between the endograft and the duodenal
repair at the time of exploratory celiotomy. All patients
were maintained on culture speciﬁc lifelong antibiotics as
determined by infectious disease prior to discharge. Most
commonly recommended antibiotics for lifelong suppres-
sion were augmentin (n ¼ 4), levaquin (n ¼ 3), or bactrim
(n ¼ 4).
Mean intensive care unit and hospital stays were and
1.82 6 2.14 (range, 0-7) and 21.8 6 15.8 (range, 8-50)
days, respectively. Postoperative complications were
uncommon in the absence of aortoenteric or aortobron-
chial ﬁstulization and included a self-resolving episode of
ischemic colitis and one distal anastomotic revision with
Fig 2. A computed tomographic angiogram (CTA) was used to assist diagnosis of endograft infection in the majority
of patients. Frequent ﬁndings included air in the sac surrounding the endograft (a) and erosion into adjacent structures
(b). In image (b), there is loss of domain noted between the aorta, esophagus, and left main stem bronchus.
Fig 3. Organisms isolated via blood or graft cultures. MRSA,
Methicillin-resistant Staphylococcus aureus.
Table IV. Mortality
Mortality,
No. (%)
P
value
All patients 7 (38)
Anatomy
EVAR (n ¼ 12) 2 (17) .03
TEVAR (n ¼ 6) 5 (83)
Presentation
No ﬁstula (n ¼ 8) 1 (13) .04
Aortic ﬁstula (n ¼ 10) 6 (60)
Management of abdominal infections
Explant (n ¼ 8) 2 (25) .39
Medical (n ¼ 4) 0 (0)
EVAR, Endovascular abdominal aortic aneurysm repair; TEVAR, thoracic
endovascular aneurysm repair.
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concomitant common iliac artery occlusion. In patients
with ﬁstulas (n ¼ 10), complications included pelvic
abscess (n ¼ 1), breakdown of duodenal stump (n ¼ 1),
thoracic empyema from esophageal leak (n ¼ 2), and anas-
tomotic duodenal ulcer with upper gastrointestinal
bleeding (n ¼ 1).
Thirty-day mortality was 28%. At a median follow-up
of 24.7 months (range, 1-75 months), aneurysm-related
mortality was 39% (n ¼ 7). Thoracic endograft infections
(P ¼ .03) and aortoenteric ﬁstulas (P ¼ .04) both corre-
lated highly with mortality (Table IV). The only survivor
of a thoracic infection was managed surgically. Overall
survival for patients with abdominal endografts was similar
between those managed surgically (n ¼ 6; 75%) or selected
for medical management (n ¼ 4; 100%) (P ¼ .39).
All patients, regardless of medical or surgical manage-
ment, underwent routine CTA imaging during follow-up
with CTA at 1, 6, and 12 months, then yearly. Median
follow-up among survivors was 17 months. There were
no infectious recurrences among survivors. Two additional
nonaneurysm related deaths occurred during follow-up.
One patient died from lung cancer 53 months after conser-
vative management of a primary aortodoudenal ﬁstula withduodenal repair, omental interposition, and aortic endo-
grafting. Another died 17 months after endograft explant
with in situ reconstruction secondary to complications of
another surgery, coronary bypass and mitral valve
replacement.DISCUSSION
Endograft infection is a rare complication after EVAR
or TEVAR with an incidence ranging from 0.05% to just
over 4%,1,2 a range which mirrors the 0.5% to 3% quoted
rates of prosthetic graft infection following open repair.5
However, the overall numbers may be increasing as we
noted a signiﬁcant increase in transfers to our institution
for management of infected endografts after 2006. The
most common isolate in this series was strep, although
the most commonly isolated organism from infected pros-
thetic grafts, after both open and endovascular operations
is typically staph.1,2 Culture results in this series may have
been swayed by the near universal administration of antibi-
otics prior to specimen collection.
The majority of the endograft infections in this series
appeared to be related to transient bacteremia with
JOURNAL OF VASCULAR SURGERY
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an infected aortic bed, many of the remaining patients had
an identiﬁable source of infection in close proximity to
their presentation with infection. This is concordant with
ﬁndings by Laser et al, who demonstrated that about
two-thirds of the patients had intervening remote sources
of infection potentially responsible for hematogenous seed-
ing of the endografts.4 Most of the endograft infections in
this series occurred early, within the ﬁrst 3 months, and
may indicate that the graft is particularly susceptible to
bacterial seeding during this time. In the canine model, it
has been demonstrated that in the presence of bacteremia,
endografts become more resistant to infection after the ﬁrst
week.6 The authors attributed this to the gross and micro-
scopic of a pseudointima formation over the endograft
material which propagated inward from the edges of the
graft. In humans, the ability of depth of stent graft incorpo-
ration has not been well documented. However, resistance
to bacteremia may not be universal or may not occur as
early as seen in the canine model. In fact, a small subgroup
of endograft infections was noted to occur in proximity to
other infectious sources as late out as 2 years post-
endografting. In Cernohorsky’s series, patients presented
with infection over 10 years after their endografts were
placed.3 These late presentations may imply that the
endograft is never fully protected from bacterial seeding.
This is a ﬁnding likely secondary to the fact that endografts
never fully incorporate. This is highly suggestive that
patients with thoracic and abdominal endografts may
require lifetime suppressive antibiotics prior to any invasive
procedures, such as is common practice with prosthetic
heart valves. Nonetheless, because of the small nature of
this series, further study would be indicated prior to any
formal recommendations.
In contrast to other series which have reported a low
incidence of aortic ﬁstulae after endografting,1 this was
the most common presentation of endograft infection
encountered in our patients, present in 56% of patients
overall. While aortoenteric ﬁstulae are a well-documented
cause of aortic graft infections after open surgery,
accounting for up to 45% of these cases,7 the high
frequency of aortic ﬁstulization after infected endografts
is not as intuitive. In the case of traditional aortic grafts,
the ﬁstula formation is believed to be caused by close prox-
imity of the graft and the surrounding tissue causing
erosion by the anastomotic suture line, or the graft itself.
Endografts, however, are completely encased within the
aortic sac and should not have the same propensity for
contact with the surrounding tissue. Intuitively active ﬁxa-
tion could be a risk factor and serve as an initial site of
enteric or bronchial injury. However, in this series and
others,8,9 endograft infections with ﬁstulization were
observed to occur with a variety of endografts including
those with and without suprarenal ﬁxation. Further, in
patients with endografts that did employ active ﬁxation
and presented with ﬁstulization, there were no cases of
observed hook penetration through the aortic and bowel
wall. While some have suggested the presence of anendoleak as a signiﬁcant risk factor for sac enlargement,
infection, and ﬁstulization,8 this was not the case here as
no patient had a documented endoleak on CTA. One
possible explanation for ﬁstulization includes the endograft
stiffness combined with increased neck tortuosity, which
may exert abnormal pressure on the bowel and adjacent
aortic sac. In addition, as evidenced by our explant experi-
ence, the aorta and surrounding tissue sometimes becomes
severely inﬂamed after endograft placement which could
contribute to ﬁstulization.10,11 Certainly, a primary infec-
tion of the endograft, which appears to be the most
common cause of endograft infection in this series, could
contribute to signiﬁcant perigraft inﬂammation and ﬁstula
formation.
In further distinction from traditional aortoenteric
ﬁstulas, as long as there is no endoleak present and no
direct connection to the endograft, these patients should
present with notably less bleeding, providing time for
patient work-up and optimization prior to operating.
Nonetheless, several of these patients without endoleak
and without a graft defect still presented with signiﬁcant
gastrointestinal bleeding. In these patients, the bleeding
was thought to be due to friable tissues of the aortic sac
and bowel wall itself. One patient additionally had erosion
of the gastrodoudenal artery from an anastomotic ulcer
postﬁstula repair, demonstrating another source of
bleeding in this region. Ultimately, ﬁstulae continue to
portend a poor prognosis even in the presence of an intact
endograft.
The gold standard of treatment for endograft infection
remains total endograft excision with arterial reconstruc-
tion and in the case of ﬁstulae, enteric or airway repair
with ﬂap coverage.1,4,8,9 Our preferred means of arterial
reconstruction for abdominal infections remains extra-
anatomic bypass with aortic stump ligation. This approach
requires a sufﬁcient length of nonfriable aorta below the
renal arteries, or with acceptance of renal failure, below
the superior mesenteric artery. In theory, extra-anatomic
reconstruction of the renal arteries (hepato-renal/spleno-
renal) could be performed, but these patients are often
quite ill and will not tolerate signiﬁcant additional proce-
dures. In situ repair with rifampin soaked graft or cryopre-
served allograft is reserved primarily for patients without an
adequate aortic stump for ligation or thoracic reconstruc-
tion where extra-anatomic bypass is less desirable. In
situ repair is avoided in the presence of gross conta-
mination or aortoenteric ﬁstula for fear of continued graft
seeding and infection. Some authors further restrict in
situ repair only for patients with all negative preoperative
cultures.4
Nonoperative management of abdominal endograft
infection is reserved for patients deemed too high-risk for
explant or for patients with more indolent presentations
and low level infections such as a bacteremia associated
with a concomitant infection without evidence of signiﬁ-
cant gross graft contamination. When conservative
management is employed, care should be individually
tailored for each patient to include an aggressive surgical
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debridement of infected wounds that may serve as an infec-
tious source in addition to intravenous antibiotic therapy.
The patients treated in this series with conservative
management of infected abdominal endografts had a high
success rate and 100% survival. However, careful patient
selection likely biased these results. With one exception,
the patients had little to no air around the graft, underwent
source control, and lifetime antibiotics. The ﬁnal patient
required duodenal repair, omental ﬂap, and reinforcing
stent graft placement for an aortodoudenal ﬁstula.
Thoracic aortic infections appear exceptionally precar-
ious in this series with a 83% mortality rate. This is likely
related in part to the high rate of early ﬁstulization. As
these infections are so rapidly progressive, we cannot at
this time, consider thoracic patients candidates for medical
therapy alone. This is reinforced by the four patients in this
series with thoracic endograft infections who were treated
conservatively with antibiotics alone; three were deemed
too high risk for repair and the last refused an operation.
All four patients died within 2 months of diagnoses. This
is consistent with prior reports of isolated medical manage-
ment for infected thoracic grafts.4 The high mortality of
thoracic graft infections is further enhanced by the
complexity of operative management compared with the
management of abdominal graft infections. Thoracic
explants frequently require thoracotomy, proximal aortic
cross clamping, cardiopulmonary bypass in many cases
and coincident esophageal or airway repair. Total endograft
excision still remains the gold standard with in situ cryopre-
served allograft or rifampin soaked grafts. Extra-anatomic
bypasses are possible but have not been our choice of
repair.12,13 In the case of thoracic aortoenteric or bronchial
ﬁstulae, primary repair of the esophagus/bronchus also
needs to be performed with an intercostal or omental ﬂap
to buttress the repair. Our sole survivor of a thoracic
endograft infection was a patient who underwent this
approach for an infected graft with an aortoesophageal
ﬁstula. Unfortunately, the other patient who underwent
thoracic endograft explant and ﬁstula repair died
postoperatively.
There is no resounding consensus on the appropriate
treatment length of antibiotics in this patient subset. We
use a 4- to 6-week treatment dose of intravenous antibi-
otics for all patients in consultation with our infectious
disease specialists. After such time, patients are transitioned
to lifetime oral suppressive antibiotics. This includes
patients who underwent graft excision, as the new graft,
whether extra-anatomic or in situ, is considered to be at
risk for infection due to the high likelihood of bacteremia
at time of surgery. In fact, when examining the risk of
recurrent prosthetic graft infection in patients after treat-
ment for aortoenteric ﬁstulae after open aortic surgery,
the rates of reinfection were signiﬁcant at 24% and 41%
at 1 and 2 years, respectively.7 Importantly, these rates
did not differ based on type of reconstruction and were
equal for those treated with extra-anatomic or in situ
repair.7It should be noted that while our experience is among
the largest series of graft infections currently reported, the
overall numbers of patients are small. This reﬂects the
fortunate rarity of this complication overall. Nonetheless,
small numbers of patients make conclusions regarding
causality and outcome difﬁcult. As such, our results may
not necessarily be generalizable. As the overall number of
patients with implanted endografts increase, the number
of patients with this problem will likely increase accord-
ingly. Continuous scrutiny and reporting will be necessary
to validate our current ﬁndings and recommendations or to
appropriately alter them.
CONCLUSIONS
Endograft infection is a rare but increasing complica-
tion after EVAR/TEVAR, which carries signiﬁcant associ-
ated morbidity and mortality. The proximity of endograft
infections to other infectious processes in the majority of
patients suggests that endograft seeding is the primary
mode of infection. This further suggests that patients
with endografts may need prophylactic antibiotics prior
to invasive procedures. In contrast to prior studies, aor-
toenteric and aortobronchial ﬁstulas are common presenta-
tions, which portend a signiﬁcantly worse prognosis.
Thoracic endograft infections, which have the highest
rate of ﬁstulization, have the worst outcomes.
In general, the degree of infection and clinical presen-
tation affect the treatment decision. In patients with gross
contamination of the graft and/or an aortoenteric ﬁstula,
explantation is strongly recommended as medical manage-
ment would unlikely resolve these issues. In patients with
more indolent presentations and low level infections such
as bacteremia associated with a concomitant infection,
medical management may be warranted. As our series is
small, it is difﬁcult to draw deﬁnitive conclusions without
more statistical power.
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